Self-Adhesive Antiviral Patch for Continuous Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical antiviral therapies for herpes simplex labialis, such as creams and ointments, are limited by frequent application needs, lack of protection for lesions, aesthetic concerns, and increased risk of contamination due to moisture-dependent adhesion requirements in existing mucoadhesive patches.
Innovation Solution
A self-adhesive patch comprising an antiviral agent dissolved in a low volatile solvent within a polymeric adhesive layer, which is soluble in highly volatile solvents, allowing continuous drug delivery and improved bioavailability without the need for pre-moistening, thereby reducing contamination risks and enhancing cosmetic acceptance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional creams or ointments are used for antiviral therapy, then the antiviral agent can be applied to the lesion, but frequent application is required and the lesion lacks protection
Solution Approach 1:
The patch provides continuous antiviral delivery through a reservoir layer that releases the antiviral agent continuously over several days, eliminating the need for frequent reapplication and ensuring sustained therapeutic action on the lesion
Solution Approach 2:
The patch uses a flexible adhesive layer that conforms to the skin and lesion surface, providing both protection and continuous drug delivery through a thin film structure that can be applied once and maintained throughout the healing process
2Reliability
If mucoadhesive patches requiring moisture for adhesion are used, then the patch can adhere to the lesion, but pre-moistening is necessary which increases contamination risk
Solution Approach 1:
The patch adhesive layer is formulated to be self-adhesive, automatically bonding to the lesion surface without requiring pre-moistening or external assistance, thereby eliminating the contamination risk associated with manual moistening while ensuring reliable adhesion
Solution Approach 2:
The adhesive layer's composition is modified to include specific polymers and excipients that enable adhesion under normal skin conditions without requiring altered moisture parameters, allowing the patch to bond reliably while maintaining hygiene standards
3Reliability
If standard topical antiviral therapies are applied, then the antiviral agent reaches the lesion, but the product visibility reduces patient compliance
Solution Approach 1:
The patch provides a discreet, thin film application that blends with the skin tone and does not create visible residue or alter the appearance of the lesion, maintaining aesthetic appearance and improving patient compliance while ensuring effective antiviral delivery
Solution Approach 2:
The patch is designed as a single-use, disposable application that is applied once and worn throughout the healing process, eliminating the need for repeated visible applications and improving cosmetic acceptance compared to recurring cream applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The patch provides continuous, effective delivery of antiviral agents like acyclovir or penciclovir, improving bioavailability and patient compliance while protecting lesions from external factors, reducing pain, and minimizing the risk of further infections.
Implementation Method 1
an antiviral agent dissolved in a low volatile solvent
Implementation Method 2
a polymeric adhesive soluble in highly volatile solvents
Implementation Method 3
continuous drug delivery without repeated daily applications
Data Source
Figure 1~2
AI summary
A patch comprising a skin adhesive layer, a backing layer and a release liner, the adhesive layer comprising an antiviral agent, a low volatile solvent, and a polymeric adhesive soluble in highly volatile solvents.